All In Biotech

Investigational drug · Phase 3

Vinflunine

Also called: Javlor

Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Bladder Cancer, Urothelial Cancer, Locally Advanced or Metastatic Unresectable Urothelial Cancer.

Phase 3

Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

3

2 still active

All registered trials

34

Any phase or sponsor naming "Vinflunine"

First trial start

2018

Mar 23, 2018

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Vinflunine", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Bladder Cancer
  • Urothelial Cancer
  • Locally Advanced or Metastatic Unresectable Urothelial Cancer

Approved drugs for the same conditions: Bladder and urothelial cancer · Oncology · Kidney and urology

Largest trials

Live from ClinicalTrials.gov: studies naming "Vinflunine" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 323 on PubMed

Also in development for Bladder Cancer

  • SKB264MK-2870, Sacituzumab TirumotecanPhase 353 trials

    Merck & Co. · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Cervical Cancer

  • Intismeran autogeneV940, mRNA-4157Phase 310 trials

    Merck & Co. · Non-small Cell Lung Cancer, Melanoma, Bladder Cancer

  • BCGPhase 38 trials

    ImmunityBio, Inc. · Non-muscle Invasive Bladder Cancer (NMIBC), Papillary-Only Non-muscle-invasive Bladder Cancer, Tuberculosis

  • CetrelimabJNJ-63723283Phase 38 trials

    Johnson & Johnson (Janssen) · Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Neoplasms

  • VisugromabCTL-002, Visugromab RDEPhase 36 trials

    CatalYm GmbH · Adult Solid Tumor, Metastatic Non-Squamous Non-Small Cell Lung Cancer, Unresectable or Metastatic Hepatocellular Carcinoma

  • TAR-200JNJ-17000139, Gemcitabine-Releasing Intravesical SystemPhase 35 trials

    Johnson & Johnson (Janssen) · Urinary Bladder Neoplasms, Non-Muscle Invasive Bladder Neoplasms, Bladder Cancer

  • Cretostimogene GrenadenorepvecCG0070Phase 34 trials

    CG Oncology, Inc. · Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer, Urologic Cancer

  • BrigimadlinBI 907828Phase 33 trials

    Boehringer Ingelheim · Solid Tumours, Pancreatic Neoplasms, Solid Tumors

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Merck & Co..

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.